About Event
The meeting serves as the definitive forum for predicting, monitoring, and mitigating adverse immune responses to AAV gene therapies, designed to equip you with the tools and insights needed to accelerate your programs safely and effectively.
Sessions will dive deep into the most pressing topics, including navigating complement activation and biodistribution to mitigate immune risks while ensuring precise, targeted delivery. Explore strategic insights into repeat dosing and immune management, equipping you to overcome barriers and extend the durability of therapeutic benefits.
This summit is jam-packed with three days of actionable case studies, interactive workshops, and thought-provoking panel discussions, empowering you to tackle immunogenicity challenges in the ‘here and now’ and position your programs for long-term success.
Navigating Immune Activation & Biodistribution
Discover how uncontrolled immune activation can lead to safety concerns such as tissue damage and inflammatory responses. Learn from Novartis' case studies on biodistribution assessments, ensuring precise transgene expression while minimizing off-target effects that could impact both safety and efficacy.
Strategic Approaches to Repeat Dosing
Explore the latest strategies for overcoming immune barriers to repeat administration, including regulatory insights and clinical experiences from Regeneron. Gain practical takeaways on how to mitigate immunogenicity while preserving long-term therapeutic efficacy.
Advancing Antibody Suppression & Removal Strategies
Dive into cutting-edge techniques for addressing pre-existing and treatment-induced immunity, with Roche leading the discussion on novel approaches tailored for rare disease applications, where immune barriers can prevent treatment altogether.
Refining Predictive Immune Models
Evaluate the latest advancements in in vivo and in vitro immune modeling with AbbVie. Learn how experts are refining translational assays to better predict patient responses and optimize safety profiles, shaping the future of preclinical testing in gene therapy.
Next-Generation Capsids for Optimized Efficacy & Safety
Analyze the most recent preclinical and clinical data from Avista Therapeutics, assessing novel capsid designs that enhance immune evasion and transduction efficiency. Understand how these innovations can reduce required dosing, improve safety, and drive commercial scalability for gene therapies.
Event in Numbers
Audience Summary
This summit brings together professionals from preclinical, clinical, translational, bioanalytical, toxicology, and pharmacology development to get the latest insights into overcoming immunogenicity bottlenecks in gene therapy development.
R&D – Discover and digest the latest and greatest in ensuring the safety and efficacy of gene therapies to gain actionable insights for your gene therapy development efforts.
Business Development – Engage with other business leaders from 40+ industry groups to set up collaborations, secure investment, and unlock future company deals.
Service Provider – We provide unique networking opportunities for leading vendors in the gene therapy field to win big business and out pace their competitors. Check out our partnership opportunities here
Academia – You will be able to leverage the latest data and tech developments from the industry into your own research and network with industry leaders in the field.